Mohit Kaushal - 12 Nov 2021 Form 4/A - Amendment Insider Report for Oncology Institute, Inc. (TOI)

Role
Director
Signature
By: /s/ Mark Hueppelsheuser, Attorney-in-Fact for Mohit Kaushal
Issuer symbol
TOI
Transactions as of
12 Nov 2021
Net transactions value
$0
Form type
4/A - Amendment
Filing time
18 Nov 2021, 19:24:47 UTC
Date Of Original Report
16 Nov 2021
Previous filing
08 Nov 2021
Next filing
23 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TOI Common Stock Options Exercise +30,000 30,000 12 Nov 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TOI Class B Common Stock Options Exercise -30,000 -100% 0 12 Nov 2021 Class A Common Stock 30,000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of Class B common stock converted into shares of the Issuer's Class A common stock on a one for basis in connection with the Business Combination (as defined below), and have no expiration date.
F2 On November 12, 2021, pursuant to that certain Agreement and Plan of Merger, dated as June 28, 2021, by and among DFP Healthcare Acquisitions Corp. ("DFP"), Orion Merger Sub I, Inc. ("First Merger Sub"), Orion Merger Sub II, LLC ("Second Merger Sub"), and TOI Parent, Inc. ("Old TOI"), First Merger Sub merged into Old TOI, with Old TOI being the surviving corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the "Business Combination. In connection with the Business Combination, the Class A common stock was converted to Common Stock of the Issuer, pursuant to a reclassification exempt under Rule 16b-7.

Remarks:

This amendment is filed in order to correct the transaction code for the conversion of Class B common stock to common stock to reflect that it is an exempt conversion pursuant to Rule 16b-3. Only the corrected transaction lines are restated in this amendment.